Healthcare Industry News: Mylan
News Release - April 13, 2009
Andrew G. Cuneo Joins Mylan as Vice President of Global Business DevelopmentPITTSBURGH, April 13 (Healthcare Sales & Marketing Network) -- Mylan Inc. (Nasdaq: MYL ) today announced the appointment of former Merrill Lynch investment banker Andrew G. Cuneo as vice president of Global Business Development. Cuneo is responsible for coordinating Mylan's global business development and strategic efforts in close alignment with the company's executive leadership team.
Mylan's Vice Chairman and CEO Robert J. Coury said: "Drew brings a wealth of experience in the pharmaceutical, biotechnology and health care sectors. His familiarity with our industry - and in particular with Mylan given his and Merrill Lynch's active role with the company during the past five years - makes him ideally suited to support the company's continued growth."
Cuneo joins Mylan from Merrill Lynch, a financial management and advisory firm, where he worked for more than a decade on strategic advisory and capital markets transactions, primarily in the health care sector. Most recently he served as a director in its Global Healthcare Investment Banking group. He earned a Bachelor of Arts in economics and psychology from Vanderbilt University.
"Mylan has emerged as one of the industry's best run and most progressive pharmaceutical franchises," said Cuneo. "I'm excited to be able to continue participating and to further contribute to the development and execution of its plans for profitable commercial expansion."
Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.Mylan.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsMylan Launches Generic Suboxone(R) Sublingual Film to Treat Opioid Dependence
Sanofi's Formulation Patents on Multibillion-Dollar Lantus(R) are Invalidated by U.S. Patent and Trademark Office via IPR, Announces Mylan
Mylan Expands Gastroenterology Portfolio with Launch of Generic for Prevacid(R) SoluTab Delayed-Release Orally Disintegrating Tablets